公开(公告)号：US20210130831A1

公开(公告)日：2021-05-06

申请号：US17084906

申请日：2020-10-30

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Junghyun KIM ,  Seong Jae KANG

IPC: C12N15/113 ,  A61K47/64 ,  A61P11/00

Abstract: The present invention relates to a lung-specific drug delivery system consisting of oligonucleotide polymers and biocompatible cationic peptides for the prevention or treatment of pulmonary fibrosis, and a use thereof. The drug delivery system according to the present invention can be specifically accumulated in the lungs and absorbed into lung fibrotic cells to knock down TGF-β, thereby preventing or treating pulmonary fibrosis.

公开(公告)号：US20240115515A1

公开(公告)日：2024-04-11

申请号：US18166782

申请日：2023-02-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Dae-Ro AHN ,  Kyoung-Ran KIM ,  Junghyun KIM ,  Ji Eun LEE ,  Ji hyun BACK

IPC: A61K9/51 ,  A61K47/54 ,  A61P1/16 ,  C12N15/113

CPC classification number: A61K9/5169 ,  A61K47/549 ,  A61P1/16 ,  C12N15/113

Abstract: The present invention relates to a liver-specific drug delivery carrier comprising a nucleic acid nanoparticle and cholesterol; a liver-specific complex; a pharmaceutical composition for prevention or treatment of liver disease using the same; and a method for preventing or treating liver disease.